Anti-viral compounds
| Title: | Anti-viral compounds |
|---|---|
| Patent Number: | 8,338,605 |
| Publication Date: | December 25, 2012 |
| Appl. No: | 12/817808 |
| Application Filed: | June 17, 2010 |
| Abstract: | Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections. |
| Inventors: | Rockway, Todd W. (Grayslake, IL, US); Betebenner, David A. (Libertyville, IL, US); Krueger, Allan C. (Gurnee, IL, US); Iwasaki, Nobuhiko (Buffalo Grove, IL, US); Cooper, Curt S. (Vernon Hills, IL, US); Anderson, David D. (Kenosh, WI, US); Kempf, Dale J. (Libertyville, IL, US); Madigan, Darold L. (Elk Grove Village, IL, US); Motter, Christopher E. (Oak Creek, WI, US); Shanley, Jason P. (Chicago, IL, US); Tufano, Michael D. (Chicago, IL, US); Wagner, Rolf (Antioch, IL, US); Zhang, Rong (Niskayuna, NY, US); Molla, Akteruzzaman (Gurnee, IL, US); Mo, Hongmei (Foster City, CA, US); Pilot-Matias, Tami J. (Green Oaks, IL, US); Masse, Sherie V. L. (Kenosha, WI, US); Carrick, Robert J. (Pleasant Prairie, WI, US); He, Wenping (Libertyville, IL, US); Lu, Liangjun (Kildeer, IL, US) |
| Assignees: | Abbott Laboratories (Abbott Park, IL, US) |
| Claim: | 1. A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula I(b), [chemical expression included] wherein: Z is —NR 41 —; A is C 6 carbocyclyl; R 10 , R 17 , R 31 , R 33 , R 35 and R 41 are each hydrogen; X is selected from the group consisting of —O—, and —S— and is ortho to Z; R 22 is carbocyclyl, heterocyclyl, carbocyclylalkyl or heterocyclylalkyl, and is optionally substituted with one or more R 26 , wherein R 26 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, alkyl, alkenyl, alkynyl, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -OS(O)R S , -L S -OSO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S″), -L S -N(R S′)C(═NR S)R S′ , -L S -N(R S)C(O)N(R S′ R S′), -L S -N═C(NR S R S′)(NR S′ R S′), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ R S′), -L E -Q-L E′ -(C 3 -C 18 -carbocyclyl) and -L E -Q-L E′ -(M 3 -M 18 heterocyclyl); or R 22 is alkyl, alkenyl or alkynyl, and is optionally substituted with one or more R 26 ; or R 22 is hydrogen; Y is selected from the group consisting of a bond, -L S -O—, -L S -C(O)—, -L S -S(O) 2 —, -L S -S(O)—, -L S -OS(O) 2 —, -L S -OS(O)—, -L S -C(O)O—, -L S -OC(O)—, -L S -OC(O)O—, -L S -C(O)N(R 15)—, -L S -N(R 15)C(O)—, -L S -C(O)N(R 15)O—, -L S -N(R 15)C(O)O—, -L S -C(O)N(R 15)N(R 15′)—, -L S -S—, -L S -C(S)—, -L S -C(S)O—, -L S -OC(S)—, -L S -C(S)N(R 15)—, -L S -N(R 15)—, -L S -N(R 15)C(S)—, -L S -N(R 15)S(O)—, -L S -N(R 15)S(O) 2 —, -L S -S(O) 2 N(R 15)—, -L S -S(O)N(R 15)—, -L S -C(S)N(R 15)O—, and -L S -C(S)N(R 15)N(R 15′)—, wherein R 15 and R 15′ are each independently selected at each occurrence from the group consisting of hydrogen, alkyl, alkenyl and alkynyl; R 50 is -L 1 -A 1 , wherein A 1 is selected from the group consisting of carbocyclyl, heterocyclyl, alkyl, alkenyl and alkynyl, and L 1 is selected from the group consisting of a bond, alkylene, alkenylene and alkynylene, wherein A 1 is optionally substituted with one or more R 30 , and R 30 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, alkyl, alkenyl, alkynyl, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S″), -L S -N(R S′)C(═NR S)R S″ , -L S -N(R S)C(O)N(R S′ R S″), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ R S″), -L E -Q-L E′ -(C 3 -C 18 -carbocyclyl) and -L E -Q-L E′ -(M 3 -M 18 heterocyclyl), and wherein L 1 is optionally substituted with one or more R 38 , and R 38 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, alkoxy, thioalkoxy, alkylcarbonyl, alkoxycarbonyl, alkylcarbonyloxy, alkylamino, alkoxycarbonylamino, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S′), -L S -N(R S′)C(═NR S)R S″ , -L S -N(R S)C(O)N(R S′ ,R S″), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ R S″), carbocyclyl, heterocyclyl, carbocyclylalkyl, heterocyclylalkyl, -L E -Q-L E -(C 3 -C 18 -carbocyclyl) and -L E -Q-L E -(M 3 -M 18 heterocyclyl); L S is independently selected at each occurrence from the group consisting of a bond, alkylene, alkenylene and alkynylene; R S , R S′ and R S″ are each independently selected at each occurrence from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, alkoxyalkyl, alkoxyalkoxyalkyl, thioalkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkylamino, alkylaminoalkyl, alkoxycarbonylamino, and alkoxycarbonylaminoalkyl; L E and L E′ are each independently selected at each occurrence from the group consisting of a bond, alkylene, alkenylene, alkynylene, -alkylene-O-alkylene-, -alkylene-S-alkylene-, -alkylene-NC(O)-alkylene-, and -alkylene-C(O)N-alkylene-; Q is independently selected at each occurrence from the group consisting of a bond, alkylene, alkenylene, alkynylene, —S—, —O—, C(O)—, —N(R S)—, —N(R S)C(O)—, —C(O)N(R S)—, —N(R S)C(O)O—, —OC(O)N(R S)—, —N(R S)C(O)N(R S′)—, —C(═NR S)N(R S′)—, —N(R S′)C(═NR S)—, —S(O)—, —SO 2 —, —O—SO 2 —, —SO 2 —O—, —S(O)—, —S(O)—O—, —C(O)O— and —C(O)—; R 15 , R 15′ , R 26 , R 30 and R 38 are each independently optionally substituted at each occurrence with at least one substituent selected from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, alkoxy, alkylamino, alkoxycarbonyl, and azido; and each C 3 -C 18 carbocyclyl and M 3 -M 18 heterocyclyl moiety in -L E -Q-L E′ -(C 3 -C 18 carbocyclyl) and -L E -Q-L E′ -(M 3 -M 18 heterocyclyl) is independently optionally substituted at each occurrence with at least one substituent selected from the group consisting of hydrogen, halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, alkyl, alkenyl, alkynyl, alkoxy, thioalkoxy, alkoxyalkyl, thioalkoxyalkyl, alkylcarbonyl, alkylcarbonylalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, alkylamino, alkylaminoalkyl, alkoxycarbonylamino, carbocyclyloxy, heterocyclyloxy, carbocycloalkoxy, heterocycloalkoxy, carbocycloalkoxycarbonyl, heterocycloalkoxycarbonyl, and alkoxycarbonylaminoalkyl. |
| Claim: | 2. The compound, tautomer, or salt of claim 1 , wherein: R 22 is carbocyclyl, heterocyclyl, carbocyclylC 1 -C 6 alkyl or heterocyclylC 1 -C 6 alkyl, and is optionally substituted with one or more R 29 , wherein R 26 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -OS(O)R S , -L S -OSO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S″), -L S -N(R S′)C(═NR S)R S″ , -L S -N(R S)C(O)N(R S′ R S″), -L S -N═C(NR S R S′)(NR S R S′), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ ,R S″), -L E -Q-L E′ -(C 3 -C 18 carbocyclyl) and -L E -Q-L E -(M 3 -M 18 heterocyclyl); or R 22 is C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and is optionally substituted with one or more R 26 ; or R 22 is hydrogen; Y is selected from the group consisting of a bond, -L S -O—, -L S -C(O)—, -L S -S(O) 2 —, -L S -S(O)—, -L S -OS(O) 2 —, -L S -OS(O)—, -L S -C(O)O—, -L S -OC(O)—, -L S -OC(O)O—, -L S -C(O)N(R 15)—, -L S -N(R 15)C(O)—, -L S -C(O)N(R 15)O—, -L S -N(R 15)C(O)O—, -L S -C(O)N(R 15)N(R 15′)—, -L S -S—, -L S -C(S)—, -L S -C(S)O—, -L S -OC(S)—, -L S -C(S)N(R 15)—, -L S -N(R 15)—, -L S -N(R 15)C(S)—, -L S -N(R 15)S(O)—, -L S -N(R 15)S(O) 2 —, -L S -S(O) 2 N(R 15)—, -L S -S(O)N(R 15)—, -L S -C(S)N(R 15)O—, and -L S -C(S)N(R 15)N(R 15′)—, wherein R 15 and R 15′ are each independently selected at each occurrence from the group consisting of hydrogenC 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl; R 50 is -L 1 -A 1 , wherein A 1 is selected from the group consisting of carbocyclyl, heterocyclyl, C 1 -C 6 alkyl, C 2 -C 6 alkenyl and C 2 -C 6 alkynyl, and L 1 is selected from the group consisting of a bond, C 1 -C 6 alkylene, C 2 -C 6 alkenylene and C 2 -C 6 alkynylene, wherein A 1 is optionally substituted with one or more R 30 , and R 30 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S″), -L S -N(R S′)C(═NR S)R S″ , -L S -N(R S)C(O)N(R S′ R S″), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ R S″), -L E -Q-L E′ -(C 3 -C 18 carbocyclyl) and -L E -Q-L E -(M 3 -M 18 heterocyclyl), and wherein L 1 is optionally substituted with one or more R 38 , and R 38 is independently selected at each occurrence from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkylamino, C 1 -C 6 alkoxycarbonylamino, -L S -O—R S , -L S -S—R S , -L S -C(O)R S , -L S -OC(O)R S , -L S -C(O)OR S , -L S -N(R S R S′), -L S -C(═NR S)R S′ , -L S -S(O)R S , -L S -SO 2 R S , -L S -C(O)N(R S R S′), -L S -N(R S)C(O)R S′ , -L S -C(═NR S)N(R S′ R S″), -L S -N(R S′)C(═NR S)R S″ , -L S -N(R S)C(O)N(R S′ R S″), -L S -N(R S)SO 2 R S′ , -L S -SO 2 N(R S R S′), -L S -N(R S)SO 2 N(R S′ R S″), carbocyclyl, heterocyclyl, carbocyclylC 1 -C 6 alkyl, heterocyclylC 1 -C 6 alkyl, -L E -Q-L E′ -(C 3 -C 18 carbocyclyl) and -L E -Q-L E -(M 3 -M 18 heterocyclyl); L S is independently selected at each occurrence from the group consisting of a bond, C 1 -C 6 alkylene, C 2 -C 6 alkenylene and C 2 -C 6 alkynylene; R S , R S′ and R S″ are each independently selected at each occurrence from the group consisting of hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 alkoxyC 1 -C 6 alkyl, C 1 -C 6 alkoxyC 1 -C 6 alkoxyC 1 -C 6 alkyl, C 1 -C 6 thioalkoxyC 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkylcarbonylC 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkoxycarbonylC 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkylcarbonyloxyC 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkylaminoC 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonylamino, and C 1 -C 6 alkoxycarbonylaminoC 1 -C 6 alkyl; L E and L E′ are each independently selected at each occurrence from the group consisting of a bond, C 1 -C 6 alkylene, C 2 -C 6 alkenylene and C 2 -C 6 alkynylene, —C 1 -C 6 alkylene-O—C 1 -C 6 alkylene-, —C 1 -C 6 alkylene-S—C 1 -C 6 alkylene-, —C 1 -C 6 alkylene-NC(O)—C 1 -C 6 alkylene-, and —C 1 -C 6 alkylene-C(O)N—C 1 -C 6 alkylene-; Q is independently selected at each occurrence from the group consisting of a bond, C 1 -C 6 alkylene, C 2 -C 6 alkenylene, C 2 -C 6 alkynylene, —S—, —O—, C(O)—, —N(R S)—, —N(R S)C(O)—, —C(O)N(R S)—, —N(R S)C(O)O—, —OC(O)N(R S)—, —N(R S)C(O)N(R S′)—, —C(═NR S)N(R S′)—, —N(R S′)C(═NR S)—, —S(O)—, —SO 2 —, —O—SO 2 —, —SO 2 —O—, —O—S(O)—, —S(O)—O—, —C(O)O— and —OC(O)—; R 15 , R 15′ , R 26 , R 30 and R 38 are each independently optionally substituted at each occurrence with at least one substituent selected from the group consisting of halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, C 1 -C 6 alkoxy, C 1 -C 6 alkylamino, C 1 -C 6 alkoxycarbonyl, and azido; and each C 3 -C 18 -carbocyclyl and M 3 -M 18 heterocyclyl moiety in -L E -Q-L E′ -(C 3 -C 18 carbocyclyl) and -L E -Q-L E′ -(M 3 -M 18 heterocyclyl) is independently optionally substituted at each occurrence with at least one substituent selected from the group consisting of hydrogen, halogen, oxo, thioxo, hydroxy, mercapto, nitro, cyano, amino, carboxy, formyl, phosphate, azido, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 1 -C 6 alkoxy, C 1 -C 6 thioalkoxy, C 1 -C 6 alkoxyC 1 -C 6 alkyl, C 1 -C 6 thioalkoxyC 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkylcarbonylC 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonyl, C 1 -C 6 alkoxycarbonylC 1 -C 6 alkyl, C 1 -C 6 alkylcarbonyloxy, C 1 -C 6 alkylcarbonyloxyC 1 -C 6 alkyl, C 1 -C 6 alkylamino, C 1 -C 6 alkylaminoC 1 -C 6 alkyl, C 1 -C 6 alkoxycarbonylamino, C 3 -C 7 -carbocyclyloxy, M 3 -M 7 heterocyclyloxy, C 3 -C 7 -carbocycloC 1 -C 6 alkoxy, M 3 -M 7 heterocycloC 1 -C 6 alkoxy, C 3 -C 7 -carbocycloC 1 -C 6 alkoxycarbonyl, M 3 -M 7 heterocycloC 1 -C 6 alkoxycarbonyl, and C 1 -C 6 alkoxycarbonylaminoC 1 -C 6 alkyl. |
| Claim: | 3. The compound, tautomer, or salt of claim 1 , wherein Y is -L S -O—, -L S -S—, -L S -C(O)N(R 15)— or -L S -N(R 15)C(O)—, R 15 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and L 1 is C 1 -C 6 alkylene optionally substituted with one or more R 38 , and wherein A 1 is a C 4 -C 6 -carbocyclyl or M 4 -M 6 heterocyclyl and is optionally substituted with one or more R 30 . |
| Claim: | 4. The compound, tautomer, or salt of claim 1 , wherein Y is -L S -O—, -L S -S—, -L S -C(O)N(R 15)— or -L S -N(R 15)C(O)—, R 15 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and L 1 is a bond, wherein A 1 is a C 4 -C 6 carbocyclyl or M 4 -M 6 heterocyclyl and is optionally substituted with one or more R 30 . |
| Claim: | 5. The compound, tautomer, or salt of claim 1 , wherein Y is -L S -O—, -L S -S—, -L S -C(O)N(R 15)— or -L S -N(R 15)C(O)—, R 15 is hydrogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl or C 2 -C 6 alkynyl, and L 1 is a bond or C 1 -C 6 alkylene optionally substituted with one or more R 38 , wherein A 1 is a bicyclic ring (e.g., a fused bicyclic ring or a bridged bicyclic ring) which has from 6 to 14 ring atoms and is optionally substituted with one or more R 30 . |
| Claim: | 6. The compound, tautomer, or salt of claim 1 , wherein R 22 is C 5 -C 6 carbocyclyl or M 5 -M 6 heterocyclyl and is optionally substituted with one or more R 26 . |
| Claim: | 7. The compound, tautomer, or salt of claim 1 , wherein R 22 is [chemical expression included] wherein R 48 is hydroxy, amino, C 1 -C 6 alkylamino, C 1 -C 6 alkoxy, C 1 -C 6 alkoxycarbonylamino or C 1 -C 6 alkylcarbonyloxy, and wherein R 22 is optionally substituted with one or more R 26 . |
| Claim: | 8. A compound, a tautomer of the compound, or a pharmaceutically acceptable salt of the compound or tautomer, wherein the compound has Formula II(b), [chemical expression included] wherein: R 2 is hydrogen; R 4 is hydrogen; R 7 is hydrogen; R 9 is selected from the group consisting of hydrogen, alkyl, alkoxy, haloalkyl, arylalkylamino, hydroxy, alkoxycarbonylaminoalkyl, alkylcarbonyl, amino, halogen, N-[alkylarylamino(arylsulfanyl)arylalkyl]-N-[(alkoxycarbonyl)alkyl]amino, alkoxyarylalkoxy, haloarylalkoxy, nitroarylalkoxy, cyanoarylalkoxy, aryloxyalkyl, haloaryloxyalkyl, cyanoalkoxy, arylalkoxy, alkylarylalkoxy, haloalkylarylaminocarbonyl, alkylaminoarylaminocarbonyl, arylalkoxy, alkylallyloxy, and alkoxycarbonyl; R 11 is hydrogen; R 12 is selected from the group consisting of arylsulfanyl, arylsulfinyl, aryloxy, and arylalkoxy; wherein R 12 is optionally substituted with one or more substituents independently selected from R 16 ; R 16 is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, amino, alkylcarbonylamino, alkylheteroarylcarbonylamino, heteroarylcarbonylamino, hydroxyheteroarylcarbonylamino, hydroxyalkylheteroarylcarbonylamino, heteroarylcarbonylaminoalkylcarbonylamino, heteroarylalkylcarbonylamino, aryloxyarylalkylcarbonylamino, allylaminocarbonyl, alkoxycarbonyl, hydroxyalkyl, arylaminocarbonyl, hydroxyarylaminocarbonyl, alkoxyalkyl, alkoxyarylaminocarbonyl, azidoalkyl, alkylaminoarylsulfonyloxy, alkylsulfonyloxy, arylalkylsulfonyloxy, alkoxycarbonylalkoxy, hydroxycarbonylalkoxy, cycloalkylcarbonylamino, arylalkoxycarbonylheterocyclecarbonylamino, aryloxy, iminoalkyl, alkylthione, arylalkylcarbonylamino, alkylaryloxyalkylcarbonylamino, arylalkoxyalkylcarbonylamino, heteroarylcarbonylaminoalkylcarbonylamino, heteroarylalkylcarbonylamino, alkylcarbonylheterocyclecarbonylamino, amino, aminocarbonyl, alkylaminocarbonyl, hydroxyalkyl, aminoalkyl, alkoxyalkylaminocarbonyl, hydroxyiminoalkyl, heteroaryl substituted with alkyl, and heteroaryl; and R 13 is hydrogen. |
| Claim: | 9. The compound, tautomer, or salt of claim 8 , wherein: R 12 is selected from the group consisting of [chemical expression included] R 14 is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, amino, alkylcarbonylamino, alkylheteroarylcarbonylamino, heteroarylcarbonylamino, hydroxyheteroarylcarbonylamino, hydroxyalkylheteroarylcarbonylamino, heteroarylcarbonylaminoalkylcarbonylamino, heteroarylalkylcarbonylamino, aryloxyarylalkylcarbonylamino, allylaminocarbonyl, alkoxycarbonyl, hydroxyalkyl, arylaminocarbonyl, hydroxyarylaminocarbonyl, alkoxyalkyl, alkoxyarylaminocarbonyl, and azidoalkyl; wherein, when R 12 is [chemical expression included] then R 16 is selected from the group consisting of hydrogen, halogen, alkyl, alkoxy, hydroxy, aminocarbonyl, alkylaminocarbonyl, amino, alkylcarbonylamino, alkylheteroarylcarbonylamino, heteroarylcarbonylamino, hydroxyheteroarylcarbonylamino, hydroxyalkylheteroarylcarbonylamino, heteroarylcarbonylaminoalkylcarbonylamino, heteroarylalkylcarbonylamino, aryloxyarylalkylcarbonylamino, allylaminocarbonyl, alkoxycarbonyl, hydroxyalkyl, arylaminocarbonyl, hydroxyarylaminocarbonyl, alkoxyalkyl, alkoxyarylaminocarbonyl, azidoalkyl, alkylaminoarylsulfonyloxy, alkylsulfonyloxy, arylalkylsulfonyloxy, alkoxycarbonylalkoxy, hydroxycarbonylalkoxy, cycloalkylcarbonylamino, arylalkoxycarbonylheterocyclecarbonylamino, aryloxy, iminoalkyl, alkylthione, arylalkylcarbonylamino, alkylaryloxyalkylcarbonylamino, arylalkoxyalkylcarbonylamino, heteroarylcarbonylaminoalkylcarbonylamino, heteroarylalkylcarbonylamino, alkylcarbonylheterocyclecarbonylamino, amino, aminocarbonyl, alkylaminocarbonyl, hydroxyalkyl, aminoalkyl, alkoxyalkylaminocarbonyl, hydroxyiminoalkyl, heteroaryl substituted with alkyl, and heteroaryl, and wherein, when R 12 is [chemical expression included] then R 16 is selected from the group consisting of aryloxyarylalkylcarbonylamino, arylaminocarbonyl, arylalkylsulfonyloxy, arylalkoxycarbonylheterocyclecarbonylamino, aryloxy, arylalkylcarbonylamino, and arylalkoxyalkylcarbonylamino. |
| Claim: | 10. The compound, tautomer, or salt of claim 8 , wherein R 9 is selected from the group consisting of hydrogen, methyl, methoxy, phenyl, trifluoromethyl, phenylmethylamino, hydroxy, t-butoxy-carbonylaminomethyl, carbonylamino, methylcarbonyl, amino, bromo, chloro, fluoro, methyl[1,8]naphthyridin-4-ylamino-(2-phenylsulfanylphen-5-ylmethyl)amino-(N-t-butoxy-carbonyl-N-methyl), methoxyphenylmethoxy, bromophenylmethoxy, nitrophenylmethoxy, cyanophenylmethoxy, trifluoromethyl, phenoxymethyl, bromophenoxymethyl, cyanomethoxy, phenylmethoxy, methylallyloxy, propoxy, methylphenylmethoxy, methylphenylmethoxy, fluoro-3-methylphenylaminocarbonyl, trifluoromethylphenylaminocarbonyl, trifluoromethylphenylaminocarbonyl, N,N-dimethylaminophenylaminocarbonyl, fluorophenylmethoxy, and chlorophenylmethoxy; and R 16 is selected from the group consisting of hydrogen, hydroxy, methylcarbonylamino, methyl, isopropyl, fluoro, methoxy, ethoxy, propoxy, isopropoxy, N,N-dimethylamino-naphth-1-ylsulfonyloxy, ethylsulfonyloxy, isopropylsulfonyloxy, methylsulfonyloxy, benzylsulfonyloxy, ethoxycarbonylmethoxy, hydroxycarbonylmethoxy, t-butylcarbonylamino, cyclopropylcarbonylamino, benzyloxycarbonylpyrrolidinylcarbonylamino, phenoxy, methylcarbonylamino, iminoethyl, thionoethyl, (S)-1-phenylpropylcarbonylamino, methylphenoxymethylcarbonylamino, (R)-1-phenyl-1-methoxymethylcarbonylamino, (S)-1-phenyl-1-methoxymethylcarbonylamino, furanylcarbonylaminomethylcarbonylamino, thienylpropylcarbonylamino, methylcarbonylpiperidinylcarbonylamino, amino, aminocarbonyl, N-methylaminocarbonyl, ethoxycarbonylmethoxy, isopropylsulfonyloxy, methylsulfonyloxy, ethylsulfonyloxy, phenylmethylsulfonyloxy, methylcarbonylamino, N-methylaminocarbonyl, hydroxymethyl, aminoethyl, methoxyethylaminocarbonyl, propylaminocarbonyl, N-methoxy-N-methylaminocarbonyl, N,N-diethylaminocarbonyl, N-(2-methoxyethyl)aminocarbonyl, N-ethyl-N-methylaminocarbonyl, N-hydroxy-1-iminoethyl, hydroxyethyl, aminomethyl, N,N-dimethylamino-carbonyl, 2,6-dimethylfuranyl, 1H-[1,2,4]triazolyl, and pyridinyl. |
| Claim: | 11. A pharmaceutical composition comprising a compound, tautomer or salt according to claim 1 . |
| Claim: | 12. A pharmaceutical composition comprising a compound, tautomer or salt according to claim 8 . |
| Claim: | 13. A compound, or tautomer or salt thereof, wherein the compound is selected from the group consisting of (5-Chloro-2-phenoxy-phenyl)-[1,6]naphthyridin-5-yl-amine; and N-{4-[4-Methyl-2-([1,6]naphthyridin-5-ylamino)-phenylsulfanyl]-phenyl}-acetamide. |
| Current U.S. Class: | 546/122 |
| Patent References Cited: | 5350749 September 1994 Hackler et al. 5464781 November 1995 Armitage et al. 5654307 August 1997 Bridges et al. 5925644 July 1999 Jakobi et al. 6130217 October 2000 Arnold et al. 6169091 January 2001 Cockerill et al. 6174889 January 2001 Cockerill et al. 6184226 February 2001 Chakravarty et al. 6277989 August 2001 Chakravarty et al. 6284764 September 2001 Kath et al. 6323180 November 2001 Llinas-Brunet et al. 6348587 February 2002 Schinazi et al. 6413971 July 2002 Arnold et al. 6476031 November 2002 Chakravarty et al. 6541481 April 2003 Bhattacharya et al. 6703403 March 2004 Norbeck et al. 6723726 April 2004 Cockerill et al. 6809097 October 2004 Thomas et al. 6903096 June 2005 Chakravarty et al. 7037913 May 2006 Wang et al. 7183302 February 2007 Romine et al. 2003/0125343 July 2003 Gambacorti-Passerini et al. 2004/0242604 December 2004 Bhattacharya et al. 2004/0265792 December 2004 Glenn et al. 2005/0075331 April 2005 Pratt et al. 2005/0090522 April 2005 Wang et al. 2005/0107364 May 2005 Hutchinson et al. 2006/0035965 February 2006 Dalton et al. 2007/0197558 August 2007 Betebenner et al. 2007/0232645 October 2007 Rockway et al. 414386 February 1991 912570 May 1999 1162196 December 2001 WO-9313097 July 1993 WO-9500511 January 1995 WO-9519774 July 1995 WO-9609294 March 1996 WO-9640142 December 1996 WO-9713771 April 1997 WO-9802428 January 1998 WO-9802437 January 1998 WO-9802438 January 1998 WO-9805661 February 1998 WO-9808846 March 1998 WO-9813350 April 1998 WO-9822444 May 1998 WO-9823613 June 1998 WO-9959587 November 1999 WO-0012497 March 2000 WO-0044728 August 2000 WO-0056738 September 2000 WO-0132153 May 2001 WO-0132632 May 2001 WO-0157040 August 2001 WO-0160315 August 2001 WO-0190121 November 2001 WO-0204425 January 2002 WO-2004014313 February 2004 WO-2004014852 February 2004 WO-2004024693 March 2004 WO-2004047818 June 2004 WO-2004055004 July 2004 WO-2004065392 August 2004 WO-2004087056 October 2004 WO-2005007652 January 2005 WO-2005047288 May 2005 WO-2005105761 November 2005 WO-2006012333 February 2006 WO-2006035061 April 2006 WO-2006038039 April 2006 WO-2006120251 November 2006 WO-2006120252 November 2006 WO-2007035010 March 2007 |
| Other References: | Venkatesh et al. Role of the Development Scientist in Compound Lead Selection and Optimization by Venkatesh et al., J. Pharm. Sci. 89, 145-54 (2000). cited by examiner Dorwald F. A. (Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim p. IX of Preface p. 1-15). cited by examiner Barlin et al., “Potential Antimalarials. I 1,8-Naphthyridines, STN Accession No. 1984:530611, Document No. 101:130611 ,” Abstract of Australian Journal of Chemistry, vol. 37 (5), pp. 1065-1173, 1984. cited by other Blight K.J. et al., “Efficient Initiation of HCV RNA Replication in Cell Culture,” Science, vol. 290, pp. 1972-1974 , 2000. cited by other Bundgaard H., “Design of prodrugs,” pp. 7-9 & 21-24, 1985. cited by other Cortese et al., “A Synthesis of Conjugatred Bile Acids. I. Glycocholic Acid,” JAGS, vol. 57, pp. 1393-1395 , 1935. cited by other Cross L.C. et al. , “Rules for the Nomenclature of Organic Chemistry—Section E: Stereochemistry,” Pure Appl. Chem., vol. 45, pp. 11-30 , 1976. cited by other Das S. et al., “A Small yeast RNA Blocks Hepatitis C Virus Internal Ribosome Entry Site (HCV IRES)-Mediated Translation and Inhibits Replication of a Chimeric Poliovirus under Translational control of the HCV IRES Element,” J of Virology, vol. 72 (7), pp. 5638-5647 , 1998. cited by other Deeb A. et al., “Pyridazine Derivatives and Related Comp9unds Part 5. Pyrazolo[3,4-c]Pyridazine: Synthesis and Some Reactoins,” Heterocycles, vol. 32 (5), pp. 895-900 , 1991. cited by other Gomtsyan A.et al., “Design, Synthesis, and Structure-Activity Relationship of 6-Alkynylpyrimidines as Potent Adenosine Kinase Inhibitors,” J. Med. Chem, vol. 45, pp. 3639-3648, 2002. cited by other Hoover J.E, Remington's Pharmaceutical Sciences, Tbl of Cont, 1975. cited by other Ikeda M. et al., “Selectable Subgenomic and Genome-Length Dicistronic RNAs Derived from an Infectious Molecular Clone of the HCV-N Strain of Hepatitis C Virus Replicate Efficiently in Clutured Huh? Cells,” J of Virology, vol. 76 (6), pp. 2997-3006, 2002. cited by other International Search Report for application No. PCT/US06/048685, Mailed on Oct. 30, 2007, 5 pages. cited by other International Search Report for application No. PCT/US06/049079, Mailed on Aug. 17, 2007, 3 pages. cited by other International Search Report for application No. PCT/US06/049080, Mailed on Aug. 23, 2007, 3 pages. cited by other International Search Report for application No. PCT/US07/088027, Mailed on Oct. 24, 2008, 1 page. cited by other Jacques et al., “Enantiomers, Racemates, and Resolutions,” J. Wiley & Sons, Chapter 3, pp. 197-213, 1981. cited by other Janout V., et al., “Design and Synthesis of Molecular Umbrellas,” I Am. Chem. Soc, vol. 119, pp. 640-647 , 1997. cited by other Lieberman H.A. et al., “Compression-Coated and Layer tablets (Tbl of Cont),” Pharmaceutical dosage forms, vol. 1, 1980. cited by other Livi et al. , “Farmaco, STN Document No. 86:89704; Abstract of Edizione Scientifica ,” vol. 31 (11), pp. 797-808, 1976. cited by other Martini C. et al., “Specific Inhibition of Benzodiazepine Receptor Binding by Some 1,2,3-Triazole Derivatives,STN Accession No. 1989:50722 Document No. 110:50722,” Abstract of Journal of Pharmaceutical Sciences, vol. 77 (11), pp. 977-980, 1988. cited by other McKenzie A. & Clough G.W, “XLVIII.—Experiments on the Ealden Inversion. Part VIII. a-Amino-a-phenylpropionic Acids,” J. Chem. Soc, vol. (101) , pp. 390-397, 1912. cited by other Miranda E.I et al., , “Thiols, Unsymmetrical Sulfides and Thioacetals From the New Reagent: Trisopropysilanethiol,” Tetrahedron Ltrs, vol. 35 (20) , pp. 3221-3224 , 1994. cited by other Nakamura S., “Studies on Growth Inhibition of hiochi-bacteria, Specific Saprophytes of Sake,” Agr. Biol. Chem, vol. 25 (8), pp. 665-670, 1961. cited by other U.S. Appl. No. 11/960,298, filed Dec. 19, 2007. cited by other Prakash, G.K.Su. et al., “Facile preparation of di- and monofluoromethyl ketones form trifluoromethyl ketones via fluorinated enol silyl ethers,” J. of Fluorine Chem, vol. 112, pp. 357-362, 2001. cited by other Refai M et al., “New Synthesis of some 1,8- Naphthyridines of Possible Antimicrobial Activity,” Egyptian Journal of Harmaceutical Sciences, National Information and Documentation Centre, vol. 37 (1-6), pp. 241-249 , 1996. cited by other Shuman R.T. et al., “Structure-Activity Study of Tripeptide Thrombin Inhibitors Using a-Alkyl Amino Lacids and Other Conformationally Constrained Amino Acid Substitutions,” I Med. Chem, vol. 38, pp. 4446-4453, 1995. cited by other Yi M. et al., “Subjenomic Hepatitis C Virus Replicaons Inducting Expression of a Secreted Enzymatic Reporter Protein,” Virology, vol. 304, pp. 197-210, 2002. cited by other |
| Primary Examiner: | Chandrakumar, Nizal |
| Attorney, Agent or Firm: | Davis, Bradley E. |
| Accession Number: | edspgr.08338605 |
| Database: | USPTO Patent Grants |
| Language: | English |
|---|